Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial

por Beatch, Gregory N., Mangal, Brian
Publicado 2016

Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia–Pacific Region: A Phase 3 Randomized Controlled Trial

por Beatch, Gregory N., Bhirangi, Kiran, Juul-Moller, Steen, Rustige, Jörg
Publicado 2017

Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 Trial

por Namdari, Rostam, Luzon, Constanza, Cadieux, Jay A., Leung, Jennifer, Beatch, Gregory N.
Publicado 2022

TMS as a pharmacodynamic indicator of cortical activity of a novel anti‐epileptic drug, XEN1101

por Premoli, Isabella, Rossini, Pierre G., Goldberg, Paul Y., Posadas, Kristina, Green, Louise, Yogo, Noah, Pimstone, Simon, Abela, Eugenio, Beatch, Gregory N., Richardson, Mark P.
Publicado 2019

Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial

por French, Jacqueline A., Porter, Roger J., Perucca, Emilio, Brodie, Martin J., Rogawski, Michael A., Pimstone, Simon, Aycardi, Ernesto, Harden, Cynthia, Qian, Jenny, Luzon Rosenblut, Constanza, Kenney, Christopher, Beatch, Gregory N.
Publicado 2023